Arbutus Biopharma

ABUS65

Penny Stock

$3.64arrow_drop_down2.14%-$0.08

Penny Stock

ABUS65

$3.64

arrow_drop_down2.14%-$0.08

Penny Stock

Performance History

Key Stats
Open	$3.73
Prev. Close	$3.73
EPS	-0.43
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$687.16M
PE Ratio	-

	LOW	HIGH
Day Range	3.60	3.84
52 Week Range	1.69	4.72

Ratios







EPS	-0.43

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Arbutus Biopharma (ABUS)

Arbutus Biopharma Corp (ABUS) is a biopharmaceutical company focused on discovering, developing, and commercializing a range of therapeutics for the treatment of chronic hepatitis B virus (HBV) infection. The company's lead product candidate, AB-729, is a subcutaneously administered RNAi agent that targets HBV. It is designed to reduce the production of viral proteins and antigens, which are key drivers of HBV replication and persistence in patients. AB-729 has shown promising results in preclinical studies, and Arbutus is currently conducting phase 1a/1b clinical trials to evaluate its safety, pharmacokinetics, and antiviral activity in healthy volunteers and patients with chronic HBV infection.

Arbutus Biopharma Corp is also conducting early-stage research and development activities in other areas, including functional cure for hepatitis B, RNA delivery, and targeted RNAi therapeutics. The company has a strong pipeline of product candidates and collaborations with leading pharmaceutical companies and academic institutions. In addition to its internal research and development efforts, Arbutus also seeks to identify and acquire promising technologies and assets to further enhance its pipeline and capabilities in the field of HBV therapeutics.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. William H. Collier
Headquarters: Warminster
Employees: 96
Exchange: NASDAQ

Keep an eye on Arbutus Biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Arbutus Biopharma's (ABUS) price per share?

The current price per share for Arbutus Biopharma (ABUS) is $3.64. The stock has seen a price change of -$0.08 recently, indicating a -2.14% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Arbutus Biopharma (ABUS)?

For Arbutus Biopharma (ABUS), the 52-week high is $4.72, which is 29.67% from the current price. The 52-week low is $1.69, the current price is 115.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Arbutus Biopharma (ABUS) a growth stock?

Arbutus Biopharma (ABUS) has shown an average price growth of -3.67% over the past three years. It has received a score of 71 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Arbutus Biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Arbutus Biopharma (ABUS) stock price performance year to date (YTD)?

As of the latest data, Arbutus Biopharma (ABUS) has a year-to-date price change of 40.54%. Over the past month, the stock has experienced a price change of -5.7%. Over the last three months, the change has been 0.55%. Over the past six months, the figure is 25.95%. Looking at a longer horizon, the five-year price change stands at 145.95%.

help

Is Arbutus Biopharma (ABUS) a profitable company?

Arbutus Biopharma (ABUS) has a net income of -$72.85M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.3K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $18.14M, although specific revenue growth data is currently not available. The gross profit is $16.74M. Operating income is noted at -$78.03M. Furthermore, the EBITDA is -$77.14M.

help

What is the market capitalization of Arbutus Biopharma (ABUS)?

Arbutus Biopharma (ABUS) has a market capitalization of $687.17M. The average daily trading volume is 3.66, indicating the stock's liquidity and investor engagement.